. 2021 Apr 3;7(5):445–452. doi: 10.1093/ehjcvp/pvab030

Table 1.

Effect of sacubitril/valsartan on glomerular filtration rate in patients with heart failure

	Comparator	Patient population	Subgroups	No.	Estimated glomerular filtration rate (mL/min/1.73 m²)
					Sacubitril/valsartan			Comparator
					Baseline	Reduction at the end of the study	Reduction per year	Baseline	Reduction at the end of the study	Reduction per year
PARAMOUNT-HF Voors et al. 2015²⁰	Valsartan	Patients with HFpEF, 42% with CKD, 38% with diabetes	All	301	66.5 ± 19	−1.5^*	−2.2^‡	64.3 ± 21	−5.2	−7.5^‡
PARADIGM-HF Damman et al. 2018³	Enalapril	Patients with HFrEF, 33% with CKD, 45% with diabetes	All	8399	70 ± 20	−7.8	−1.61^†	70 ± 20	−10.2	−2.04
			No CKD	5654			−1.98^§			−2.29
			CKD	2745			−0.80^†			−1.55
PARADIGM-HF (secondary analysis) Packer et al., 2018³⁰			No Diabetes	4615			−1.0^†			−1.3
			Diabetes	3784			−1.7^†			−2.3
PARAGON-HF McCausland et al 2020²⁹	Valsartan	Patients with HFpEF, 47% with CKD, 43% with diabetes	All	4822	63 ± 19	−7.7^‡	−2.0^†	62 ± 19	−10.1^‡	−2.7

Data from randomized controlled trials vs. angiotensin receptor blocker (valsartan) or angiotensin-converting enzyme inhibitor (enalapril).

P = 0.002 vs. comparator;

^†

P ≤ 0.001 vs. comparator;

^‡

calculated;

^§

P < 0.05.